Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PKI-402 |
| Synonyms | |
| Therapy Description |
PKI-402 is a dual ATP-competitive mTOR/PI3K inhibitor, which leads to reduced downstream signaling, potentially resulting in decreased tumor growth (PMID: 20371716, PMID: 32585451). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PKI-402 | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 | PKI-402 is a dual ATP-competitive mTOR/PI3K inhibitor, which leads to reduced downstream signaling, potentially resulting in decreased tumor growth (PMID: 20371716, PMID: 32585451). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN loss | glioblastoma | sensitive | PKI-402 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PKI-402 inhibited tumor growth in PTEN-negative glioblastoma multiforme cell line xenograft models (PMID: 20371716). | 20371716 |
| PIK3CA E545K | breast cancer | sensitive | PKI-402 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with PKI-402 resulted in decreased Akt phosphorylation and tumor regression in ERBB2 (HER2)-positive breast cancer cell line xenograft models harboring PIK3CA E545K (PMID: 20371716). | 20371716 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|